Neurocrine Biosciences (NBIX) Stock Forecast & Price Target

Neurocrine Biosciences is attractive because its core franchises are already producing strong, scalable growth, with 2Q26 revenue of $959 million, up 39% year over year, and non-GAAP EPS of $2.85, up 73% year over year, while Ingrezza posted $716 million in 2Q26 and received a FY26 guidance raise to $2.825-2.875 billion. The outlook is further supported by Crenessity’s continued launch execution, with 3Q26 sales estimated at $210 million versus $201 million consensus and FY 2026 at $772 million versus $756 million, plus Vykat XR’s expected return to growth after the 3Q26 discontinuation overhang clears. Beyond the commercial base, the company has a well-funded pipeline with roughly 10 readouts in 2027 and multiple late-stage assets in MDD and schizophrenia, giving investors additional upside from a cash-generative platform rather than a single-product story.

Neurocrine Biosciences is pressured by a concentration in Ingrezza, where tardive dyskinesia growth may slow and the 2029 IRA Maximum Fair Price is expected to lift the gross-to-net deduction to 28.7% from 19.6%, cutting FY29E revenue to $2,990MM from $3,375MM. Its second major product, Crenessity, faces a small Huntington’s chorea market already served by two approved drugs and a competitive threat in CAH from atumelnant, which could further limit pricing power and share gains. The pipeline also adds uncertainty because psychiatry programs carry binary execution risk, while VYKAT XR launch uptake depends on a 25-30% steady-state roll-off, leaving the broader story vulnerable to slower growth, competition, and margin pressure.